Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8286314 | 0.91 | MEN1 (0.39) | MEN1KMT2AALDH1A1KDM4ENPSR1 | |
| SCHEMBL1571548 | 0.82 | EGFR (0.35) | ALDH1A1SMN1; SMN2DGAT1 | |
| SCHEMBL13108209 | 0.80 | KEAP1 (0.46) | MEN1KMT2AALDH1A1KDM4ENPSR1 | |
| SCHEMBL18949530 | 0.78 | MEN1 (0.41) | MEN1KMT2AALDH1A1KDM4ENPSR1 | |
| SCHEMBL3816097 | 0.77 | TDP1 (0.44) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL2083264 | 0.77 | MEN1 (0.40) | MEN1KMT2AALDH1A1KDM4ENPSR1 | |
| SCHEMBL2083262 | 0.76 | MEN1 (0.39) | MEN1KMT2AALDH1A1KDM4ENPSR1 | |
| SCHEMBL29980565 | 0.76 | MEN1 (0.39) | MEN1KMT2AALDH1A1KDM4ENPSR1 | |
| SCHEMBL2083261 | 0.76 | MEN1 (0.39) | MEN1KMT2AALDH1A1KDM4ENPSR1 | |
| SCHEMBL29457319 | 0.76 | MEN1 (0.39) | MEN1KMT2AALDH1A1KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251194-A1 | ANTINEOPLASTIC DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-7816406-B2 | Quinolone analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816406-B2 | Quinolone analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100063046-A1 | TETRACYCLIC IMIDAZOLE ANALOGS | SENHWA BIOSCIENCES, INC. (TW) | 2010-03-11 | — | — | US | disclosed |
| US-20100063046-A1 | TETRACYCLIC IMIDAZOLE ANALOGS | SENHWA BIOSCIENCES, INC. (TW) | 2010-03-11 | — | — | US | disclosed |
| WO-2008060693-A2 | TETRACYCLIC IMIDAZOLE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063046-A1 | TETRACYCLIC IMIDAZOLE ANALOGS | BAD, API5, MCL1 | MEN1 1156/4885KMT2A 2089/4885ALDH1A1 3035/4885 |
| US-20110251194-A1 | ANTINEOPLASTIC DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MCL1, PAICS, SLCO1B1 | MEN1 410/4885KMT2A 3405/4885ALDH1A1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.